Chemotherapy-induced hypogonadism

Chemotherapy-induced hypogonadism is an endocrine and reproductive complication characterized by gonadal failure resulting from the cytotoxic effects of antineoplastic agents It affects oncology patients receiving systemic chemotherapy—particularly regimens containing alkylating agents or platinum compounds—and impairs either the testes or ovaries

Chemotherapy-induced hypogonadism is an endocrine and reproductive complication characterized by gonadal failure resulting from the cytotoxic effects of antineoplastic agents It affects oncology patients receiving systemic chemotherapy—particularly regimens containing alkylating agents or platinum compounds—and impairs either the testes or ovaries Pathophysiologically, cytotoxic damage directly disrupts gonadal tissue, inducing germ cell depletion and Leydig or granulosa cell dysfunction

Pathophysiologically, cytotoxic damage directly disrupts gonadal tissue, inducing germ cell depletion and Leydig or granulosa cell dysfunction

This manifests primarily as primary hypergonadotropic hypogonadism marked by suppressed sex steroid concentrations, compensatory elevations in follicle-stimulating hormone and luteinizing hormone, infertility, fatigue, vasomotor instability, and sexual dysfunction

This manifests primarily as primary hypergonadotropic hypogonadism marked by suppressed sex steroid concentrations, compensatory elevations in follicle-stimulating hormone and luteinizing hormone, infertility, fatigue, vasomotor instability, and sexual dysfunction

This manifests primarily as primary hypergonadotropic hypogonadism marked by suppressed sex steroid concentrations, compensatory elevations in follicle-stimulating hormone and luteinizing hormone, infertility, fatigue, vasomotor instability, and sexual dysfunction